Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications

被引:48
作者
Duque, Alice [1 ]
Mediano, Mauro Felippe Felix [1 ,2 ]
De Lorenzo, Andrea [1 ]
Rodrigues Jr, Luiz Fernando [1 ,3 ]
机构
[1] Inst Nacl Cardiol, Educ & Res Dept, Rua Laranjeiras 374, BR-22240006 Rio De Janeiro, RJ, Brazil
[2] Evandro Chagas Natl Inst Infect Dis, Oswaldo Cruz Fdn, Lab Clin Res Chagas Dis, BR-21040360 Rio De Janeiro, RJ, Brazil
[3] Univ Fed Rio de Janeiro, Inst Biomed, Dept Physiol Sci, BR-22240006 Rio De Janeiro, RJ, Brazil
关键词
Cardiovascular autonomic neuropathy; Cardiac autonomic neuropathy; Diabetes mellitus; Heart rate variability; Sympathetic autonomic nervous system; Parasympathetic autonomic nervous system; HEART-RATE-VARIABILITY; RISK-FACTORS; CARDIAC DENERVATION; OXIDATIVE STRESS; NERVOUS-SYSTEM; QT INTERVAL; MORTALITY; DIAGNOSIS; DYSFUNCTION; IMPACT;
D O I
10.4239/wjd.v12.i6.855
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular autonomic neuropathy (CAN) is a debilitating condition that mainly occurs in long-standing type 2 diabetes patients but can manifest earlier, even before diabetes is diagnosed. CAN is a microvascular complication that results from lesions of the sympathetic and parasympathetic nerve fibers, which innervate the heart and blood vessels and promote alterations in cardiovascular autonomic control. The entire mechanism is still not elucidated, but several aspects of the pathophysiology of CAN have already been described, such as the production of advanced glycation end products, reactive oxygen species, nuclear factor kappa B, and pro-inflammatory cytokines. This microvascular complication is an important risk factor for silent myocardial ischemia, chronic kidney disease, myocardial dysfunction, major cardiovascular events, cardiac arrhythmias, and sudden death. It has also been suggested that, compared to other traditional cardiovascular risk factors, CAN progression may have a greater impact on cardiovascular disease development. However, CAN might be subclinical for several years, and a late diagnosis increases the mortality risk. The duration of the transition period from the subclinical to clinical stage remains unknown, but the progression of CAN is associated with a poor prognosis. Several tests can be used for CAN diagnosis, such as heart rate variability (HRV), cardiovascular autonomic reflex tests, and myocardial scintigraphy. Currently, it has already been described that CAN could be detected even during the subclinical stage through a reduction in HRV, which is a non-invasive test with a lower operating cost. Therefore, considering that diabetes mellitus is a global epidemic and that diabetic neuropathy is the most common chronic complication of diabetes, the early identification and treatment of CAN could be a key point to mitigate the morbidity and mortality associated with this long-lasting condition.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Predictors of cardiovascular autonomic neuropathy in patients with type 1 diabetes
    Monteiro Tannus, Lucianne Righeti
    Guerra Drummond, Karla Rezende
    da Silva Clemente, Eliete Leao
    Bevilacqua da Matta, Maria de Fatima
    Gomes, Marilia Brito
    FRONTIERS IN ENDOCRINOLOGY, 2014, 5
  • [22] Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment
    Balcioglu, Akif Serhat
    Muderrisoglu, Haldun
    WORLD JOURNAL OF DIABETES, 2015, 6 (01) : 80 - 91
  • [23] Cardiac Autonomic Neuropathy in Diabetes Mellitus: Pathogenesis, Epidemiology, Diagnosis and Clinical Implications: A Narrative Review
    Gogan, Alexandra
    Potre, Ovidiu
    Avram, Vlad-Florian
    Andor, Minodora
    Caruntu, Florina
    Timar, Bogdan
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (03)
  • [24] Evaluating treatment options for cardiovascular autonomic neuropathy in patients with diabetes mellitus: a systematic review
    Goh, Jasmine KaiLi
    Koh, Leroy
    DIABETOLOGY INTERNATIONAL, 2023, 14 (03) : 224 - 242
  • [25] Diabetic cardiovascular autonomic neuropathy: clinical significance, diagnosis and therapy
    Kempler, Peter
    Korei, Anna
    ORVOSI HETILAP, 2024, 165 (16) : 602 - 612
  • [26] Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis
    Chowdhury, Mahin
    Nevitt, Sarah
    Eleftheriadou, Aikaterini
    Kanagala, Prathap
    Esa, Hani
    Cuthbertson, Daniel J.
    Abd Tahrani
    Alam, Uazman
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (02)
  • [27] Diabetic Cardiovascular autonomic Neuropathy
    Ziegler, Dan
    DIABETOLOGIE UND STOFFWECHSEL, 2017, 12 (01) : 28 - 40
  • [28] Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives
    Fisher, Victoria L.
    Tahrani, Abd A.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2017, 10 : 419 - 434
  • [29] Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients
    Pop-Busui, Rodica
    Backlund, Jye-Yu C.
    Bebu, Ionut
    Braffett, Barbara H.
    Lorenzi, Gayle
    White, Neil H.
    Lachin, John M.
    Soliman, Elsayed Z.
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (01) : 125 - 133
  • [30] Screening of Cardiovascular Autonomic Neuropathy in Patients with Diabetes by Quick and Simple Assessment of Sudomotor Function
    Calvet, J. H.
    Dupin, J.
    Deslypere, J. P.
    JOURNAL OF DIABETES & METABOLISM, 2012, 3 (04)